Misonix Introduces BoneScalpel® MIS Platform and Trains More Than 120 Surgeons At The 2015 North American Spine Society Annual Meeting

FARMINGDALE, N.Y., Oct. 21, 2015 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery, wound and burn care, and other surgical specialties, successfully introduced the new BoneScalpel MIS Platform to more than 120 of the world's leading spine surgeons, including several surgeon key opinion leaders ("KOLs") last week at the annual North American Spine Society ("NASS") meeting in Chicago, IL.

Following various hands-on demonstrations and podium presentations by KOLs, including Dr. Juan Uribe, Dr. Isador Lieberman, Dr. Nicholas Renaldo, and Dr. Connor Telles, "it's clear that the BoneScalpel system is having a large impact in a growth market," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. He also commented that "we are excited to have engaged more than 120 of the world's leading spine surgeons and extremely pleased with the surgeon turnout at our booth and during the BoneScalpel presentations at the NASS Solutions Showcase. Overall traffic to our booth and BoneScalpel presentations this year increased by more than 230% from 2014."

The increase in attendance can be attributed to the awareness generated by the Better Matters branding campaign in conjunction with the standing room only attendance at NASS Solutions Showcase followed by multiple "Meet the Expert" sessions. "The new BoneScalpel MIS product was well received by my surgeon colleagues at the NASS Solutions Showcase," explained Dr. Juan Uribe, University of South Florida, Tampa, FL. He further commented that, "The BoneScalpel MIS is a game changer for minimally-invasive spine procedures," and that he was, "excited to be a part of the team introducing this new product." 

Surgeons who attended the presentations also received hands-on training throughout the event through various "Meet the Expert" sessions, which allowed for peer-to-peer demonstrations and explanations of the BoneScalpel system and the new BoneScalpel MIS product. They highlighted the benefits of the product, including controlled bone cutting and removal, which reduces bone bleeding and is soft-tissue sparing.  While demonstrating the BoneScalpel product to his peers, Dr. Connor Telles, Sierra Pacific Orthopedics, Fresno, CA, also commented, "In my spine surgery practice, I choose to use the BoneScalpel in all of my procedures as it provides more control than traditional instruments and reduces bone bleeding while protecting the neural elements." 

Mr. McManus concluded by commenting, "We are proud to be working with an esteemed group of key opinion leaders who are on the forefront of spine surgery. This surgeon team, along with the  Misonix team, surpassed our expectations this year in building even greater appreciation of the BoneScalpel's capabilities and awareness of the new BoneScalpel MIS Platform. We intend to capitalize on this momentum and anticipate that the interest in BoneScalpel, expressed by surgeons at this meeting, will translate into more patients benefiting from this unique technology."

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.

Related Links

http://www.misonix.com